Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
about
T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevanceReview: Gout: A Roadmap to Approaches for Improving Global OutcomesSevere Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationThe genetics of gout: towards personalised medicine?Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysisIntroducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study.Validation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B*58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions.Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project.Recent advances in the understanding of severe cutaneous adverse reactions.Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.Gout: An old disease in new perspective - A review.HLAs: Key regulators of T-cell-mediated drug hypersensitivity.HLA Association with Drug-Induced Adverse Reactions.PSORS1C1 Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese.Clinical practice guidelines in China.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese PopulationClinical evaluation of a substitute of HLA-B*58:01 in different Chinese ethnic groups
P2860
Q26747638-5B1D33F0-6B42-424A-BE17-97F2178A2396Q28076018-62283657-5AC2-4A93-929B-1B0F8AC77191Q28076600-1E529BE9-A848-49AB-BCA8-95A86D9B7B63Q33750522-F9D3C26A-13A1-4BF8-B714-AB65359F4184Q34557668-27D7E17A-BB95-4F1A-979A-910CE2F662B1Q37240086-5299B085-4594-4846-80CF-206B60B147FBQ37306211-BCDA2994-A418-4AC5-BBB3-FD9299BDA570Q37404888-344B57C5-ED22-4ABC-B7C9-FD5ADFF37245Q37697237-943FCDF4-1AD6-4881-B60D-86951F69BF01Q38600529-FC10DA13-5C46-484F-BC48-C151B5343348Q38644685-8477968D-EAD4-4A56-9B61-A6274C45EC8BQ38801991-00906EB7-3E07-4B77-BAC0-ED21C827A102Q38931289-9AB01A61-103D-47DA-A115-899A0BFC7D84Q39062032-7D09BBE9-4047-4720-8366-B7E6623FC8D4Q40106739-A286BDAF-E2C1-4AF5-AC07-1736544DAEE8Q47320133-1BEC5975-53EC-40B9-A53A-A53D618B982DQ47553722-F2915DE4-1C61-4779-82DC-14CE7A00244CQ49247755-A7FBC30B-0738-4269-A260-D3EBC9BDD264Q49628481-91CF40BD-5E83-48FD-A0C1-85EF47F940FBQ50115047-E875E787-6727-477F-8771-F830F70D54ACQ54664040-14E886DF-A322-4DDA-AAA4-A067D910611AQ57557226-E98CAF70-17FE-42C5-8E15-0B51E07F5846Q58802746-5979C12A-D916-4CD6-A45B-585DF992CC6C
P2860
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@ast
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@en
type
label
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@ast
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@en
prefLabel
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@ast
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@en
P2093
P2860
P356
P1433
P1476
Use of HLA-B*58:01 genotyping ...... onal prospective cohort study.
@en
P2093
Chang-Youh Tsai
Chen-Ching Wu
Chen-Hung Chen
Chia-Li Yu
Chia-Shuo Chang
Chia-Tse Weng
Chia-Wen Wang
Chien-Hsiun Chen
Chih-Sheng Chu
Chih-Shung Wong
P2860
P356
10.1136/BMJ.H4848
P407
P577
2015-09-23T00:00:00Z